News
BYLieve showed activity of alpelisib plus fulvestrant with manageable toxicity in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, after progression on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback